Niagen Biosciences Reports Positive Results from First-Ever Randomized Trial of Niagen NR in Long COVID Patients.

Niagen Biosciences reported results from its first randomized trial of Niagen NR in long COVID patients. The study found that participants receiving Niagen NR experienced improvements in fatigue, sleep quality, and mood, with NAD+ levels increasing up to 3.1-fold. The results support further exploration of NAD+ restoration as a therapeutic strategy for long COVID, with larger studies needed to validate the findings. Niagen Biosciences plans to expand research into NAD+ biology and post-viral recovery.